Quidel to Present at William Blair 39th Annual Growth Stock Conference
May 21 2019 - 6:00PM
Business Wire
Quidel Corporation (NASDAQ: QDEL), a provider of rapid
diagnostic testing solutions, cellular-based virology assays and
molecular diagnostic systems, announced today that it will present
at the William Blair 39th Annual Growth Stock Conference
at the Loews Chicago hotel in Chicago, Illinois on
Thursday, June 6, 2019.
Randy Steward, chief financial officer, will present on
Thursday, June 6, 2019 at 1:20 p.m. Central Time (11:20 a.m.
Pacific Time) with a question-and-answer session scheduled
immediately following the presentation. During the presentation,
the company will discuss business and financial developments and
trends. The company's statements may contain or constitute material
information that has not been previously disclosed.
A live webcast and audio archive of the presentation will be
available via the Investor Relations section of the company’s
website at http://ir.quidel.com or by clicking the link below:
http://wsw.com/webcast/blair55/qdel/
Participants should allow approximately five to ten minutes
prior to the presentation's start time to visit the site and
download any streaming media software needed to listen to the
Internet webcast. A replay of the webcast will also be available on
the company’s website for 14 days.
About Quidel Corporation
Quidel Corporation serves to enhance the health and
well-being of people around the globe through the development of
diagnostic solutions that can lead to improved patient outcomes and
provide economic benefits to the healthcare system. Marketed under
the Sofia®, QuickVue®, D3® Direct Detection, Thyretain®, Triage®
and InflammaDry® leading brand names, as well as under the new
Solana®, AmpliVue® and Lyra® molecular diagnostic brands,
Quidel’s products aid in the detection and diagnosis of many
critical diseases and conditions, including, among
others, influenza, respiratory syncytial virus, Strep A,
herpes, pregnancy, thyroid disease and fecal occult
blood. Quidel's recently acquired Triage® system of tests
comprises a comprehensive test menu that provides rapid,
cost-effective treatment decisions at the point-of-care (POC),
offering a diverse immunoassay menu in a variety of tests to
provide diagnostic answers for quantitative BNP, CK-MB, d-dimer,
myoglobin, troponin I and qualitative TOX Drug Screen. Quidel’s
research and development engine is also developing a continuum of
diagnostic solutions from advanced immunoassay to molecular
diagnostic tests to further improve the quality of healthcare in
physicians’ offices and hospital and reference laboratories. For
more information about Quidel’s comprehensive product portfolio,
visit quidel.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190521005968/en/
Quidel Contact:Quidel CorporationRandy StewardChief Financial
Officer(858) 552-7931
Media and Investors Contact:Quidel CorporationRuben Argueta(858)
646-8023rargueta@quidel.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jul 2023 to Jul 2024